Nurix Therapeutics Initiates Pivotal Phase 2 for Bexobrutideg in CLL, Reports Strong Data & Outlines 2026 Goals
NRIX has more than doubled off its 52-week low of $8.18.
Summary
Nurix Therapeutics announced the initiation of its pivotal Phase 2 DAYBreak CLL-201 study for bexobrutideg, reporting strong clinical data that positions it as a potential best-in-class BTK degrader, and outlined key pipeline and financial goals for 2026.
Key Events · Product Development and Regulatory · NRIX
-
Pivotal Phase 2 Study Initiated
Nurix commenced the DAYBreak CLL-201 pivotal Phase 2 study for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL), targeting accelerated approval.
-
Strong Clinical Data for Bexobrutideg
Updated Phase 1a data for bexobrutideg showed an 83% objective response rate and 22.1-month median progression-free survival in r/r CLL, outperforming a recently approved competitor in a more heavily pretreated patient group.
-
Confirmatory Phase 3 Planned
A randomized confirmatory Phase 3 trial (DAYBreak CLL-306) comparing bexobrutideg to pirtobrutinib is planned for 2026 to support full approval.
-
Robust Financial Position
The company reported a pro forma cash and investments balance of $663.8 million, bolstered by a $250 million follow-on offering in October 2025.
Analysis · NRIX · Life Sciences
This 8-K details significant progress for Nurix Therapeutics, particularly with its lead asset, bexobrutideg. The initiation of the pivotal DAYBreak CLL-201 Phase 2 study for accelerated approval in relapsed/refractory CLL is a major de-risking event. The reported Phase 1a data, showing an 83% objective response rate and 22.1-month median progression-free survival in a heavily pretreated population, compares favorably to a recently FDA-approved competitor, pirtobrutinib, suggesting a potential best-in-class profile. The company's plan to initiate a confirmatory Phase 3 trial against pirtobrutinib in 2026 further underscores its confidence. Additionally, positive Phase 1a data for the immuno-oncology asset NX-1607 and progress in partnered inflammation and immunology programs highlight a robust pipeline. A strong pro forma cash position of $663.8 million provides ample runway for these ambitious development plans. Investors should monitor the progress of the DAYBreak trials and further clinical data readouts.
At the time of this filing, NRIX was trading at $19.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $8.18 to $22.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.